| Yvonne L. Greenstreet |
Yvonne L. Greenstreet was the founder of Highgate LLC, a company founded in 2014, where she held the title of Managing Director from 2014 to 2016. Currently, Dr. Greenstreet holds multiple positions. She is the Chief Executive Officer & Director at Alnylam Pharmaceuticals, Inc. since 2016. She is also a Member of The Association of the British Pharmaceutical Industry and a Member-Discovery Council at Harvard Medical School. Dr. Greenstreet has held several former positions. From 2008 to 2010, she was a Director at Molecular Insight Pharmaceuticals, Inc. In 2014, she served as an Independent Non-Executive Director at Indivior PLC until 2019. From 2014 to 2023, she was an Independent Director at Pacira Biosciences, Inc. She also served as a Director at The American Funds Group and as a Non-Executive Director at argenx SE from 2021 to 2022. Additionally, she held the position of an Independent Non-Executive Director at Advanced Accelerator Applications SA. From 2015 to 2018, she was an Independent Director at Moelis & Co. From 2010 to 2013, she was the Senior Vice President & Head-Medicines Development at Pfizer Inc. And from 2008 to 2010, she served as the Chief Strategy-R&D, Senior Vice President at GSK Plc. Dr. Greenstreet's education includes an undergraduate degree from the University of Leeds in 1985 and an MBA from INSEAD in 1991. |
| Piyush Sharma |
Piyush Sharma is currently the Chief Ethics & Compliance Officer at Alnylam Pharmaceuticals, Inc. Prior to his current position, he worked as the Senior Vice President & Head-Compliance at Alexion Pharmaceuticals, Inc. from 2017 to 2022. He also served as the Chief Compliance Counsel at Pfizer Inc. Mr. Sharma holds a graduate degree from Fordham University School of Law and an undergraduate degree from Brown University. |
| Pushkal P. Garg |
Pushkal P. Garg is an Independent Director at SQZ Biotechnologies Co. since 2018 and the Chief Medical Officer & Executive VP-Development at Alnylam Pharmaceuticals, Inc. since 2014. Previously, he worked as the Vice President-Global Clinical Research at Bristol Myers Squibb Co. Dr. Garg completed his undergraduate degree at the University of California, Berkeley and holds a doctorate degree from The University of California, San Francisco. |
| Timothy J. Maines |
Timothy J. Maines is currently the Chief Technical Operations & Quality Officer at Alnylam Pharmaceuticals, Inc. He previously worked as the Director-Quality Assurance at Stryker Corp., Vice President-Corporate Quality at MedImmune LLC, Vice President-Quality Assurance at ARIAD Pharmaceuticals, Inc., Vice President-Quality at Omthera Pharmaceuticals, Inc., and Vice President-Corporate Quality at rEVO Biologics, Inc. He completed his undergraduate degree at Gannon University. |
| Jeffrey V. Poulton |
Jeffrey V. Poulton is currently a Non-Executive Director at EIP Pharma, Inc., a Director at Alnylam UK Ltd., a Director at CervoMed, Inc., and the Chief Financial Officer & Executive Vice President at Alnylam Pharmaceuticals, Inc. Previously, he served as the Chief Financial Officer & Executive Director at Shire Plc from 2015 to 2017. He was also an Independent Director at Homology Medicines, Inc. from 2020 to 2022, and the Chief Financial Officer at Indigo Ag, Inc. from 2018 to 2019. Mr. Poulton obtained his undergraduate degree from Duke University and holds an MBA from Kelley School of Business. |
| Saraswathy V. Nochur |
Saraswathy V. Nochur is currently the Chairman at Hospitality Homes and an Independent Director at Marinus Pharmaceuticals, Inc. She is also a Director at Biomedical Sciences Careers Program, Inc. and the Chief Diversity, Equity & Inclusion Officer at Alnylam Pharmaceuticals, Inc. Her former positions include being a Director of New Product Development at DynaGen, Inc., Director of Product Development & Regulatory Affairs at Ischemix, Inc., Independent Director at Decibel Therapeutics, Inc. from 2021 to 2023, Vice President of Regulatory Affairs at The Medicines Co., and COO and VP of Product Development & Regulatory Affairs at Biotrack, Inc. Dr. Nochur holds a doctorate degree from the Massachusetts Institute of Technology and undergraduate and graduate degrees from the University of Mumbai. |
| James P. Bilotta |
James P. Bilotta is currently the Chief Information Officer & SVP at Alnylam Pharmaceuticals, Inc. Prior to this, he worked as the Chief Information Officer & Vice President at Alexion Pharmaceuticals, Inc. from 2012 to 2014 and as the Senior Manager-Information Technology at Purdue Pharma LP from 2000 to 2004. He holds an undergraduate degree and an MBA from Southern Connecticut State University. |
| Evan Lippman |
Evan Lippman is currently the Chief Corporate Development & Strategy Officer at Alnylam Pharmaceuticals, Inc. Prior to his current position, he held the role of Senior VP, Chief Financial & Business Officer at Aileron Therapeutics, Inc. from 2015 to 2016. He also served as the Senior Vice President-Neurodegenerative Diseases at EMD Serono, Inc. and as the President & Chief Operating Officer at Intima Bioscience, Inc. Mr. Lippman completed his undergraduate studies at Bucknell University and Georgia State University. He holds an MBA from Cornell University. |
| Tolga Tanguler |
Tolga Tanguler is currently the Chief Commercial Officer at Alnylam Pharmaceuticals, Inc. He previously worked as a Director at Ferrosan Holding A, Regional President-North America at Pfizer Inc., and Senior Vice President at Alexion Pharmaceuticals, Inc. He holds an MBA from Michigan State University and an undergraduate degree from Istanbul University. |
| Michael W. Bonney |
Michael W. Bonney's current jobs include Chairman at Dunad Therapeutics Ltd., Chairman at Autolus Therapeutics Plc, Non-Independent Director at Alnylam Pharmaceuticals, Inc., Director at Gulf of Maine Research Institute, Director at Life Sciences Cares, and Director at X-Biotix Therapeutics, Inc. Former jobs include Chairman at Bates College, Chairman at Gulf of Maine Research Institute, Chairman at Kaleido Biosciences, Inc., Chairman at Magenta Therapeutics, Inc., Chairman at Rare LLC (Virginia), Independent Director at Bristol Myers Squibb Co., Independent Director at Celgene Corp., Independent Director at NPS Pharmaceuticals, Inc., Director at Cubist Pharmaceuticals LLC, Independent Director at Sarepta Therapeutics, Inc., Director at Tekla Capital Management LLC, Director at Pharmaceutical Research & Manufacturers of America, Director at Trius Therapeutics, Inc., Director at Pharmaceutical Manufacturers Association of America, Director-National Business at Zeneca Pharmaceuticals, Independent Director at Global Blood Therapeutics, Inc., Director at Syros Pharmaceuticals, Inc., Director at Revolution Medicines, Inc., Independent Trustee at abrdn Healthcare Investors, Independent Trustee at abrdn Life Sciences Investors, Vice President-Sales & Marketing at Biogen, Inc., Member at Biotechnology Innovation Organization, Trustee at abrdn World Healthcare Fund, Trustee at Beth Israel Deaconess Medical Center, Inc., Partner at Third Rock Ventures LLC, and Independent Trustee at abrdn Healthcare Opportunities Fund. Education history includes an undergraduate degree from Bates College. |
| Kevin Fitzgerald |
Kevin Fitzgerald is currently an Independent Director at Ovid Therapeutics, Inc. since 2021. He is also the Chief Scientific Officer, EVP & Head-Research at Alnylam Pharmaceuticals, Inc. since 2005. Dr. Fitzgerald completed his undergraduate degree at Cornell University and his doctorate degree at Princeton University. |
| Kelley Boucher |
Kelley Boucher is currently a Member of the Healthcare Businesswomens Association. She is also the Chief Human Resource Officer at Alnylam Pharmaceuticals, Inc. Additionally, she is a Member of the Human Resource Leadership Forum and CEB Global Ltd. In the past, Ms. Boucher held the position of Vice President-Human Resources at ABIOMED, Inc. and Head-Human Resources at Shire Pharmaceuticals, Inc. She completed her undergraduate degree at Cornell University. |
| Amy L. Schulman |
Amy L. Schulman is the founder of Lyndra Therapeutics, Inc. (founded in 2015) and LS Polaris Innovation Fund (founded in 2017). She is also the founder of Suono Bio, Inc. Ms. Schulman's current job(s) include being the Chairman of SQZ Biotechnologies Co. since 2015 and the Chairman of Alnylam Pharmaceuticals, Inc. since 2014. She is also a Director at Pet Products, Inc., Wesleyan University, The Mount Sinai Hospital, Equal Justice Works, Action Against Hunger-USA, Kallyope, Inc., Cardurion Pharmaceuticals LLC, Thirty Madison, Inc., Glympse Bio, Inc., Dewpoint Therapeutics, Inc., ByHeart, Inc., Candesant Biomedical, Inc., Volastra Therapeutics, Inc., Amagma, Inc., Vico Therapeutics BV, Hudson Executive Investment Corp. II, Larkspur Biosciences, Inc., and a Managing Partner at Polaris Growth Management LLC. Ms. Schulman's former job(s) include being the Chief Executive Officer of Eagle Biologics, Inc. from 2014 to 2016, the Executive Chairman & Chief Executive Officer of Olivo Laboratories LLC, an Independent Director at Ironwood Pharmaceuticals, Inc. from 2017 to 2019, a Director at DNIB Unwind, Inc. from 2014 to 2016, the Lead Independent Director at Arsanis, Inc. from 2015 to 2019, a Director at Zoetis, Inc. from 2012 to 2013, a Director at Whitehead Institute for Biomedical Research, a Director at Brooklyn Academy of Music, an Independent Director at Blue Buffalo Pet Products, Inc., a Director at Quentis Therapeutics, Inc., an Independent Director at Cyclerion Therapeutics, Inc. from 2019 to 2020, an Independent Director at Hudson Executive Investment Corp., the Executive Vice President & General Counsel at Wyeth LLC, the President-Vaccines, Oncology & Consumer Healthcare at Pfizer Inc. from 2013 to 2014, a Member at The Brookings Institution, and a Partner at DLA Piper LLP (United States). Ms. Schulman's education includes an undergraduate degree from Wesleyan University and a graduate degree from Yale Law School (conferred in 1989). |
| Akshay K. Vaishnaw |
Akshay K. Vaishnaw is an Independent Director at Editas Medicine, Inc. since 2016. He is also a Director at Scholar Rock, Inc. since 2019 and an Independent Director at Scholar Rock Holding Corp. since 2019. Additionally, he serves as the Chief Innovation Officer at Alnylam Pharmaceuticals, Inc. since 2006. Dr. Vaishnaw previously worked as a Senior Director-Translational Medicine at Biogen, Inc. from 1998 to 2005 and as a Director at Visterra, Inc. from 2014 to 2018. He holds a doctorate degree from the University of London, a undergraduate degree from the University of Cardiff, and a doctorate degree from Cardiff University School of Medicine. |
| Olivier Brandicourt |
Olivier Brandicourt currently works at AvenCell Therapeutics, Inc., as Chairman, Alnylam Pharmaceuticals, Inc., as Independent Director from 2020, National Committee on United States-China Relations, Inc., as Director, BeiGene Ltd., as Independent Non-Executive Director from 2024, Dewpoint Therapeutics, Inc., as Director from 2020, BenevolentAI SA, as Independent Non-Executive Director from 2022, and International Federation of Pharmaceutical Manufacturers, as Council Member. Dr. Brandicourt also formerly worked at Sanofi-Aventis (Singapore) Pte Ltd., as Chief Executive Officer, Sanofi, as Chief Executive Officer & Director from 2015 to 2019, Pharmaceutical Research & Manufacturers of America, as Chairman in 2019, The Children's Aid Society, Inc., as Vice Chairman, Sanofi Biotechnology SAS, as Chairman, Bayer HealthCare AG, as Chairman-Management Board from 2013 to 2015, Pfizer Manufacturing Ireland Unlimited Co., as Managing Director in 2007, Pfizer Ltd., as Managing Director from 2004 to 2007, Pfizer Inc., as President & General Manager-Emerging Markets in 2013, Warner-Lambert Co., as Vice President from 1998 to 2000, Bayer AG, as Executive Council Member, European Federation of Pharmaceutical Industries & Assns, as Vice President & Member, Parke, Davis & Co. LLC, as Vice President & General Manager from 1998 to 2000, and Odyssey Acquisition SA, as Principal. Dr. Brandicourt received his graduate degree and doctorate degree from Universite Paris Est Creteil Val De Marne and undergraduate degree from Université de Paris 5 René Descartes. |
| Margaret A. Hamburg |
Margaret A. Hamburg is currently the Director at GAVI Alliance, Independent Director at Alnylam Pharmaceuticals, Inc., Director at the American Museum of Natural History, Director at the Council on Foreign Relations, Inc., Director at The Commonwealth Fund, Director at The Nature Conservancy, Inc., Ex-Officio Director at the Foundation for the National Institutes of Health, Inc., Director at the Simons Foundation, Director at The Parker Institute For Cancer Immunotherapy, and Trustee at The Urban Institute. Previously, Dr. Hamburg served as Director at Henry Schein, Inc. from 2003 to 2009, Director at The Aaron Diamond AIDS Research Center, President & Director at the American Association for the Advancement of Science, Director & Senior Scientist at the Nuclear Threat Initiative, Inc. from 2001 to 2009, Health Commissioner for the City of New York from 1991 to 1997, Commissioner of the US Food & Drug Administration from 2009 to 2015, Assistant Secretary-Planning & Evaluation at the US Department of Health & Human Services from 1997 to 2001, and Secretary of the National Academy of Medicine from 2015 to 2020. Dr. Hamburg holds a doctorate degree from Harvard Medical School and an undergraduate degree from Harvard College. |
| Charles Elliott Sigal |
Charles Elliott Sigal is currently serving as a Director at Medarex, Inc. He is also an Independent Director at Alnylam Pharmaceuticals, Inc., Vir Biotechnology, Inc., Affinia Therapeutics, Inc., and Tessera Therapeutics, Inc. Additionally, he holds positions as a Member of the Drug Discovery & Development Forum at the National Academy of Medicine (United States) and a Member of the President Council at The J. David Gladstone Institutes. Dr. Sigal is a Trustee at University Medical Center and manages Segal Family Investments LLC. In his former roles, Dr. Sigal served as the Chief Executive Officer and Vice President of R&D at Mercator Genetics, Inc. He was also the Director, Chief Scientific Officer, and Executive VP at Bristol Myers Squibb Co. from 2011 to 2013. Additionally, he held the position of Director at Mead Johnson Nutrition Co. from 2012 to 2017. Dr. Sigal served as an Independent Director at Spark Therapeutics, Inc. from 2014 to 2019 and as an Independent Non-Executive Director at Surface Oncology, Inc. from 2018 to 2023. He also served as an Independent Non-Executive Director at Adaptimmune Therapeutics Plc from 2015 to 2023. Furthermore, Dr. Sigal was a Non-Executive Director at Adaptimmune Ltd.Dr. Sigal obtained his doctorate degree from The University of Chicago in 1981. He pursued his graduate studies at Purdue University and completed his undergraduate and second doctorate degrees there in 1973 and 1977, respectively. |
| Phillip Allen Sharp |
Phillip Allen Sharp is the founder of Dewpoint Therapeutics, Inc. (founded in 2018), Biogen, Inc. (founded in 1978), PPD Dermatology LLC (founded in 2006), and Alnylam Pharmaceuticals, Inc. (founded in 2002). He is currently the Director at Whitehead Institute for Biomedical Research, The Broad Institute, Inc., Vir Biotechnology, Inc., Massachusetts Institute of Technology, The Royal Society, National Academy of Sciences, American Academy of Arts & Sciences, National Academy of Medicine (United States), American Philosophical Society, and David H. Koch Institute for Integrative Cancer Research. He has formerly held positions as the Director at Center for Cancer Research (1985-1991), Director & Strategic Advisor at Longwood Fund Management LLC, Independent Director at Syros Pharmaceuticals, Inc. (2012-2022), and Director at McGovern Institute For Brain Research (2000-2004). He received his undergraduate degree from Union College (Kentucky) in 1966 and his doctorate degree from the University of Illinois in 1969. |
| Peter N. Kellogg |
Peter N. Kellogg is currently serving as an Independent Director at Alnylam Pharmaceuticals, Inc. and as a Director at Juno Therapeutics, Inc. He is also a Non-Executive Director at Idorsia Ltd. and a Director at Idorsia Pharmaceuticals Ltd. Additionally, he holds the position of Chief Financial Officer & Executive Vice President at Receptos LLC. In his former roles, Mr. Kellogg served as an Independent Director at Yield10 Bioscience, Inc. from 2007 to 2020. He was also the Chief Financial Officer & Executive Vice President at Biogen MA, Inc. from 2000 to 2003, and at Merck & Co., Inc. from 2007 to 2014. Furthermore, he held the position of Senior Vice President-eCommerce at PepsiCo, Inc. in 2000, and Chief Financial Officer & Executive Vice President at Schering-Plough Corp. in 2009. He also served as the Chief Financial Officer & Executive Vice President at Biogen, Inc. from 2003 to 2007. Mr. Kellogg's education includes an undergraduate degree from Princeton University in 1978 and an MBA from The Wharton School of the University of Pennsylvania in 1982. |
| Dennis Arthur Ausiello |
Dennis Arthur Ausiello is currently the Vice Chairman at Spexis Ltd. He is also a Director at TARIS BioMedical LLC, KinDex Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Research!America, Institute for Human Genetics & Research, Seres Therapeutics, Inc., Rani Therapeutics LLC, Center For Assessment Technology & Continuous Health, EnBiotix, Inc., Rani Therapeutics Holdings, Inc., and a Member of the National Academy of Sciences, American Academy of Arts & Sciences, National Academy of Medicine (United States), and the Institute of Medicine of The National Academies of Science. He serves on the Board of Advisors at InCube Venture Partners LLC and is a Professor-Clinical Medicine at Harvard Medical School. In the past, Dr. Ausiello served as the Lead Independent Director at Pfizer Inc. from 2015 to 2019. He was also a Director at Fraunhofer USA, Inc., The Broad Institute, Inc., and Tarveda Therapeutics, Inc. He held the position of Chief Medicine Officer at The General Hospital Corp. from 1996 to 2011 and Chief Scientific Officer at Mass General Brigham, Inc. from 1996 to 2013. Additionally, he was the President of the Association of American Physicians. Dr. Ausiello holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Harvard College. |
| Colleen F. Reitan |
Colleen F. Reitan is an Independent Director at Myriad Genetics, Inc. since 2019, at Alnylam Pharmaceuticals, Inc. since 2018, and at Cricket Health, Inc. since 2019. She previously served as a Director at MEDecision, Inc., Prime Therapeutics LLC, and Availity LLC. From 2015 to 2018, she was the President-Plan Operations & Executive VP at Health Care Service Corp. She also held the position of President & Chief Operating Officer at BCBSM, Inc. from 2006 to 2008. Ms. Reitan completed her undergraduate degree at Minnesota State University-Mankato and her graduate degree at the University of Minnesota. |
| Carolyn R. Bertozzi |
Carolyn R. Bertozzi is the founder of Redwood Bioscience, Inc. (founded in 2008), Palleon Pharmaceuticals, Inc. (founded in 2015), Venn Biosciences Corp. (founded in 2017), and Lycia Therapeutics, Inc. (founded in 2019). Dr. Bertozzi is also the founder of Firefly Bio, Inc., Enable Biosciences, Inc... Dr. Bertozzi's current job(s) include being an Independent Director at Alnylam Pharmaceuticals, Inc. since 2023, a Director at Grace Science Foundation, an Independent Director at OmniAb Operations, Inc., a Director at OmniAb, Inc. since 2022, a Director at Stanford Chem-H since 2021, a Professor at Stanford University, and a Member of various organizations such as the American Chemical Society, The Royal Society, and the National Academy of Sciences. Dr. Bertozzi's former job(s) include being an Independent Director at Eli Lilly & Co. from 2017 to 2021, a Director-Molecular Foundry at Lawrence Berkeley National Laboratory, a Director at The Broad Institute, Inc., a Director at Catalent, Inc., a Director at Molecular Foundry, and a Professor at the University of California, Berkeley from 1996 to 2015. Dr. Bertozzi's education includes an undergraduate degree from Harvard University in 1988 and a doctorate degree from the University of California, Berkeley in 1993. |
| David E. I. Pyott |
David E. I. Pyott is currently the Chief Executive Officer & Director at Serica Technologies, Inc. He is also the Chairman at Bioniz Therapeutics, Inc., Vice Chairman at Chapman University, Chairman-Governing Board at London Business School, Independent Director at BioMarin Pharmaceutical, Inc., Director at MAP Pharmaceuticals LLC, Director at Biotechnology Innovation Organization, Independent Director at Alnylam Pharmaceuticals, Inc., Director at Pan-American Ophthalmological Foundation, Director at Cosmetic Surgery Foundation, Inc., Director at Paul Merage School of Business, Independent Director at Pliant Therapeutics, Inc., Independent Member-Supervisory Board at Koninklijke Philips NV, President at Vicept Therapeutics, Inc., President at International Council of Ophthalmology Foundation, Vice President and President at Ophthalmology Foundation, and Trustee at California Institute of Technology. Formerly, Mr. Pyott served as the Chairman & Chief Executive Officer at Allergan, Inc., President & Chief Executive Officer at Sandoz Nutrition Corp., Lead Independent Director at Avery Dennison Corp., Independent Director at Edwards Lifesciences Corp., Director at Pacific Mutual Holding Co., Director at Pacific LifeCorp, Director at California Healthcare Institute, Director at Rani Therapeutics LLC, and Head-Nutrition Division at Novartis AG. Mr. Pyott holds a graduate degree from The University of Edinburgh and an MBA from London Business School (conferred in 1980). |
